Biogen board nominee is mother of director's child; Sanders pushes NIH on 'reasonable pricing' for drugs

Taking stock of the drug industry, from the lab to the medicine chest

June 13, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Anna Moneymaker/Getty Images STAT+ | Sanders wants NIH to adopt 'reasonable pricing' language for drugs that agency research helps develop "Now is the time for the Biden administration to take executive action to substantially lower the price of prescription drugs," said Sanders. By Ed Silverman STAT+ | Biotech executive nominated to Biogen board is mother of director's child, records show Longtime and polarizing director Alex Denner, who is stepping down from the board, is the romantic partner of Susan Langer. By Damian Garde and Adam Feuerstein 'The drug bust paradox': Study shows opioid deaths double after police action A dealer's arrest, researchers theorize, leads customers to find dealers whose drugs have more dangerous adulterants. By Lev Facher Adobe STAT+ | Moving past regulatory obstacles, Protagonist Therapeutics looks to pivotal trial for its rare blood disorder therapy A rare blood disorder therapy got some primetime attention at the European Hematology Association's annual meeting. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser